WaveMan
WaveMan · Company
IPSC · Century Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IPSC Century Therapeutics (IPSC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001850119
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
65
13F, latest reported quarter

What the filings say about IPSC

Insiders, 180 days
-$22.1K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$9.3K
3 notices

Century Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Century Therapeutics, Inc. insiders sold a net $22.1K of stock across 67 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Carr Douglas
SVP Finance & Operations
SELL
2026-09-15 SECtraded 2026-09-14
1,658
$3.2K
-23.7%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Sep 8, 2026.
  • The trade is 0.3% of the 502,907 shares held after it.
  • 1 other insider sold within 30 days.
  • 65 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP Finance & Operations Carr Douglas sold about $3.2K of IPSC on Sep 14, 2026; 1 other insider sold within 30 days and 65 funds added in the latest 13F quarter.
Russotti Gregory
See Remarks
SELL
2026-09-15 SECtraded 2026-09-14
2,587
$5.0K
-23.7%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Sep 8, 2026.
  • The trade is 0.5% of the 509,198 shares held after it.
  • 1 other insider sold within 30 days.
  • 65 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Russotti Gregory sold about $5.0K of IPSC on Sep 14, 2026; 1 other insider sold within 30 days and 65 funds added in the latest 13F quarter.
Russotti Gregory
See Remarks
SELL
2026-09-09 SECtraded 2026-09-08
534
$1.1K
-26.8%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Jun 12, 2026.
  • The trade is 0.1% of the 511,785 shares held after it.
  • 1 other insider sold within 30 days.
  • 65 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Russotti Gregory sold about $1.1K of IPSC on Sep 8, 2026; 1 other insider sold within 30 days and 65 funds added in the latest 13F quarter.
Carr Douglas
SVP Finance & Operations
SELL
2026-09-09 SECtraded 2026-09-08
254
$521
-26.8%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Aug 3, 2026.
  • The trade is 0.1% of the 504,565 shares held after it.
  • 1 other insider sold within 30 days.
  • 65 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP Finance & Operations Carr Douglas sold about $521 of IPSC on Sep 8, 2026; 1 other insider sold within 30 days and 65 funds added in the latest 13F quarter.
Carr Douglas
SVP Finance & Operations
SELL
2026-08-05 SECtraded 2026-08-03
275
$544
-25.3%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Jun 12, 2026.
  • The trade is 0.1% of the 504,819 shares held after it.
  • No other insider sold within 30 days.
  • 65 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP Finance & Operations Carr Douglas sold about $544 of IPSC on Aug 3, 2026; 65 funds added in the latest 13F quarter.
67 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 62 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$22.1K over 180 days
-$10.4K over 90 days
more than 59% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
65 funds bought in last quarter
more than 54% of Pharma & Biotech
Revenue
+1556.8% year over year
more than 97% of Pharma & Biotech
Margin
-8.8% net margin
more than 65% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
28.8% of the float short (float per yahoo 2026-10-27) · 29.2 days to cover · settled 2026-10-15
more than 88% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IPSC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+140.7%12M
-21%+119%+258%+398%2025-102025-122026-022026-042026-062026-082026-10 2025-12-22 · Cowan Chad bought $49.4K2025-12-12 · Pfeiffenberger Brent bought $30.2K2026-03-12 · Russotti Gregory sold $25.7K2026-03-12 · Carr Douglas sold $18.0K2025-11-19 · Pfeiffenberger Brent bought $17.5K2025-11-17 · Pfeiffenberger Brent sold $14.6K2026-06-12 · Russotti Gregory sold $5.8K2026-09-14 · Russotti Gregory sold $5.0K2026-06-12 · Carr Douglas sold $3.7K2026-09-14 · Carr Douglas sold $3.2K2025-11-20 · Cowan Chad sold $2.7K2026-03-09 · Russotti Gregory sold $1.2K2026-06-08 · Russotti Gregory sold $1.1K2026-09-08 · Russotti Gregory sold $1.1K2026-03-09 · Carr Douglas sold $6272026-05-04 · Carr Douglas sold $6182026-02-03 · Carr Douglas sold $5882026-08-03 · Carr Douglas sold $5442026-06-08 · Carr Douglas sold $5252026-09-08 · Carr Douglas sold $5212025-12-08 · Russotti Gregory sold $2792025-11-03 · Carr Douglas sold $1722025-12-08 · Carr Douglas sold $1362026-09-14 · Carr Douglas filed to sell $3.2K2026-09-14 · Russotti Gregory filed to sell $5.0K2026-09-08 · Russotti Gregory filed to sell $1.1K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IPSC: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
17,754,430 sh
$43.5M
TCG Crossover Management, LLC
17,754,430 sh
$43.4M
Versant Venture Management, LLC
12,166,109 sh
$29.8M
Deep Track Capital, LP
9,462,645 sh
$23.2M
RTW INVESTMENTS, LP
8,695,652 sh
$21.3M

Congress trades in IPSC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IPSC planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Carr Douglas
Filed 2026-09-14
$3.2K
Russotti Gregory
Filed 2026-09-14
$5.0K
Russotti Gregory
Filed 2026-09-08
$1.1K

IPSC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Small Cap Value Fund
$1.3M position · as of 2026-06-30
0.2%
iShares Micro-Cap ETF
$1.0M position · as of 2026-06-30
0.1%
1290 VT Micro Cap Portfolio
$67.9K position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$422.4K position · as of 2026-06-30
0.0%
iShares Russell 2000 Value ETF
$2.7M position · as of 2026-06-30
0.0%
PD Small-Cap Value Index Portfolio
$21.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
1
Not applicable
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $22.1K sold by insiders over 180 days, 65 funds added last quarter, $9.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IPSC financials

Revenue growth
+1556.8%
XBRL, annual
Net margin
-8.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$109.2M
four quarters, 2025-01-01 to 2025-12-31
Net margin, TTM
-100.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$88.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.04x
long-term debt only, 2023-03-31 (39 months older than the period end); equity 2026-06-30
Cash flow to debt
-8.35x
TTM operating cash flow over long-term debt only, 2023-03-31 (39 months older than the period end)
Return on equity
-49.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-38.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-43.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$217.9M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term debt only, 2023-03-31 (39 months older than the period end), minus cash 2026-06-30
FCF yield
-34.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$109.2M$6.6M$2.2M$5.2M
Operating income-$17.3M-$138.1M-$146.5M-$133.8M
Net income-$9.6M-$126.6M-$136.7M-$130.9M
EPS (diluted)-0.14-1.61-2.30-2.96
Operating cash flow-$103.9M-$110.1M-$88.3M$14.1M
Cash$61.9M$58.4M$47.3M$84.3M
Long-term debtn/an/an/a$3.7M
SEC XBRL, fiscal years, as known on 2026-10-28

IPSC Stock Sonar score 6/7 axes

Find similar shapesCompare

IPSC ranks highest on growth (74th percentile) and profitability (55th), and lowest on insider conviction (29th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
55
Inputs
  • Return on equity-49.7% · 53 pct, sector of 545
  • Return on assets-38.4% · 54 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-43.2% · 57 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.04x · 64 pct, sector of 352
  • Cash flow to debt-8.35x · 24 pct, sector of 371
Growth
74
Inputs
  • Revenue growth, YoY+1557% · 97 pct, sector of 505
  • Backlog growth, YoY-0.0% · 51 pct, sector of 40
Insider conviction
29
Inputs
  • Net Form 4 buying (codes P and S), 180d-$22K · 57 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
54
Inputs
  • Funds adding, latest quarter65 · 54 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
30
Inputs
  • Short interest, % of float+28.8% · 5 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+9.5% · 56 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IPSC filings, in plain words

Are Century Therapeutics insiders buying or selling IPSC?

In the 180 days to 2026-10-28, Century Therapeutics insiders were net sellers, a net $22.1K across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of IPSC?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $9.3K of stock; the latest, by Carr Douglas, was filed 2026-09-14.

Read the full summary

In the 180 days to 2026-10-28, Century Therapeutics insiders were net sellers of IPSC, a net $22.1K across purchases and sales reported on Form 4 by 2 sellers. None of the 10 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $9.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies